Stock listing
Dusseldorf:4E2 Relmada Therapeutics, Inc. Aktie
German listing (Dusseldorf) of Relmada Therapeutics, Inc. · home listing NASDAQ:RLMD
Follow Relmada Therapeutics, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:RLMD
$2.62 USD -0.23 (-8.2%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:RLMD
- Day range
- $2.60 – $3.13 USDNov 20, 2026
- Volume
- 2.25M sharesNov 20, 2026
- Market cap
- $279.5M USDAt the close on Nov 20, 2026 · price × 106.7M shares outstanding
- 52-week range
- $2.60 – $8.00 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $5.41M USDMedian day 1.31M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:RLMD · Home | $2.62 USD | -0.235 (-8.2%) | 2,249,760 | $3.07 | $3.13 | $2.603 | $2.855 | Close on Nov 20, 2026 |
| Frankfurt:4E2 | €2.68 EUR | +0.14 (+5.5%) | — | €2.68 | €2.68 | €2.68 | €2.54 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:RLMD · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $2.62 | -0.235 | -8.2% | $3.07 | $3.13 | $2.603 | 2,249,760 | |
| $2.855 | -0.155 | -5.1% | $2.96 | $3.091 | $2.85 | 1,860,810 | |
| $3.01 | -0.60 | -16.6% | $3.55 | $3.60 | $2.98 | 2,089,497 | |
| $3.61 | -0.60 | -14.3% | $4.11 | $4.14 | $3.455 | 2,418,931 | |
| $4.21 | +0.05 | +1.2% | $4.70 | $4.71 | $3.815 | 1,736,265 | |
| $4.16 | -0.27 | -6.1% | $4.40 | $4.47 | $4.135 | 1,038,496 | |
| $4.43 | +0.16 | +3.7% | $4.26 | $4.525 | $4.21 | 1,504,388 | |
| $4.27 | +0.13 | +3.1% | $4.11 | $4.31 | $4.11 | 985,677 | |
| $4.14 | +0.24 | +6.2% | $3.98 | $4.185 | $3.91 | 958,590 | |
| $3.90 | +0.13 | +3.4% | $3.81 | $3.97 | $3.69 | 1,055,409 | |
| $3.77 | -0.40 | -9.6% | $4.325 | $4.325 | $3.685 | 1,486,558 | |
| $4.17 | -0.10 | -2.3% | $4.34 | $4.60 | $4.11 | 2,635,234 | |
| $4.27 | +0.43 | +11.2% | $3.88 | $4.31 | $3.88 | 2,663,624 | |
| $3.84 | +0.26 | +7.3% | $3.61 | $3.93 | $3.595 | 2,256,995 | |
| $3.58 | +0.14 | +4.1% | $3.42 | $3.655 | $3.30 | 1,413,751 | |
| $3.44 | +0.09 | +2.7% | $3.38 | $3.485 | $3.29 | 1,609,780 | |
| $3.35 | +0.14 | +4.4% | $3.21 | $3.36 | $3.18 | 1,614,697 | |
| $3.21 | -0.02 | -0.6% | $3.22 | $3.33 | $3.175 | 1,673,657 | |
| $3.23 | -0.04 | -1.2% | $3.30 | $3.305 | $3.215 | 775,829 | |
| $3.27 | -0.02 | -0.6% | $3.26 | $3.335 | $3.18 | 1,100,741 | |
| $3.29 | +0.08 | +2.5% | $3.27 | $3.41 | $3.15 | 6,281,293 | |
| $3.21 | -0.15 | -4.5% | $3.35 | $3.395 | $3.19 | 1,720,536 | |
| $3.36 | +0.20 | +6.3% | $3.17 | $3.395 | $3.16 | 740,282 | |
| $3.16 | +0.06 | +1.9% | $3.11 | $3.21 | $3.075 | 746,309 | |
| $3.10 | -0.10 | -3.1% | $3.21 | $3.29 | $3.07 | 1,279,415 | |
| $3.20 | -0.04 | -1.2% | $3.27 | $3.35 | $3.185 | 909,041 | |
| $3.24 | -0.12 | -3.6% | $3.31 | $3.37 | $3.195 | 1,354,317 | |
| $3.36 | -0.15 | -4.3% | $3.50 | $3.55 | $3.355 | 1,424,367 | |
| $3.51 | +0.12 | +3.5% | $3.39 | $3.535 | $3.315 | 1,423,670 | |
| $3.39 | +0.22 | +6.9% | $3.18 | $3.535 | $3.155 | 1,730,502 | |
| $3.17 | -0.08 | -2.5% | $3.23 | $3.32 | $3.10 | 1,886,414 | |
| $3.25 | -0.03 | -0.9% | $3.26 | $3.355 | $3.24 | 1,497,317 | |
| $3.28 | -0.20 | -5.7% | $3.50 | $3.50 | $3.265 | 1,735,689 | |
| $3.48 | -0.12 | -3.3% | $3.60 | $3.70 | $3.415 | 1,282,546 | |
| $3.60 | -0.06 | -1.6% | $3.72 | $3.73 | $3.60 | 1,209,548 | |
| $3.66 | -0.11 | -2.9% | $3.73 | $3.80 | $3.65 | 1,358,477 | |
| $3.77 | +0.04 | +1.1% | $3.78 | $3.845 | $3.72 | 999,525 | |
| $3.73 | -0.06 | -1.6% | $3.82 | $3.89 | $3.695 | 863,545 | |
| $3.79 | -0.04 | -1.0% | $3.80 | $3.855 | $3.71 | 986,628 | |
| $3.83 | +0.02 | +0.5% | $3.81 | $3.87 | $3.73 | 1,311,049 | |
| $3.81 | +0.03 | +0.8% | $3.74 | $3.875 | $3.66 | 1,325,332 | |
| $3.78 | -0.46 | -10.8% | $4.26 | $4.26 | $3.77 | 1,130,083 | |
| $4.24 | +0.08 | +1.9% | $4.16 | $4.27 | $4.145 | 662,654 | |
| $4.16 | +0.04 | +1.0% | $4.13 | $4.235 | $4.075 | 552,734 | |
| $4.12 | -0.08 | -1.9% | $4.15 | $4.17 | $4.06 | 2,069,829 | |
| $4.20 | -0.02 | -0.5% | $4.28 | $4.39 | $4.18 | 772,911 | |
| $4.22 | -0.22 | -5.0% | $4.45 | $4.572 | $4.205 | 824,376 | |
| $4.44 | 0.00 | 0.0% | $4.44 | $4.495 | $4.30 | 1,998,635 | |
| $4.44 | -0.08 | -1.8% | $4.52 | $4.56 | $4.42 | 1,264,731 | |
| $4.52 | +0.45 | +11.1% | $4.60 | $4.65 | $4.295 | 2,629,279 | |
| $4.07 | -0.02 | -0.5% | $4.25 | $4.25 | $4.00 | 2,808,981 | |
| $4.09 | -0.16 | -3.8% | $4.24 | $4.28 | $4.09 | 1,590,041 | |
| $4.25 | -0.18 | -4.1% | $4.40 | $4.425 | $4.13 | 1,697,806 | |
| $4.43 | +0.06 | +1.4% | $4.35 | $4.44 | $4.32 | 675,555 | |
| $4.37 | -0.17 | -3.7% | $4.55 | $4.58 | $4.33 | 847,511 | |
| $4.54 | +0.08 | +1.8% | $4.54 | $4.593 | $4.365 | 1,416,552 | |
| $4.46 | +0.10 | +2.3% | $4.31 | $4.51 | $4.31 | 944,057 | |
| $4.36 | +0.03 | +0.7% | $4.31 | $4.395 | $4.285 | 628,242 | |
| $4.33 | -0.19 | -4.2% | $4.51 | $4.53 | $4.32 | 678,358 | |
| $4.52 | -0.03 | -0.7% | $4.53 | $4.58 | $4.485 | 496,494 | |
| $4.55 | -0.04 | -0.9% | $4.57 | $4.60 | $4.46 | 476,693 | |
| $4.59 | +0.01 | +0.2% | $4.63 | $4.725 | $4.57 | 1,025,383 | |
| $4.58 | -0.05 | -1.1% | $4.64 | $4.64 | $4.375 | 935,748 | |
| $4.63 | -0.01 | -0.2% | $4.68 | $4.76 | $4.54 | 985,172 | |
| $4.64 | -0.19 | -3.9% | $4.74 | $4.79 | $4.55 | 1,033,935 |
Splits
2 splits since 2015 · NASDAQ:RLMD · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-4 | Consolidation | |
| 1-for-5 | Consolidation |
- Ticker
- Dusseldorf:4E2
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Dusseldorf
- Currency
- EUR
What changed lately
Latest news release · Nov 16, 2026
Relmada Therapeutics Appoints Uro-Oncology Leader Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officer
Latest earnings call · Nov 12, 2026
Relmada Therapeutics (NASDAQ:RLMD) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Nov 12, 2026
Investor Presentation (November 2026)
Investor deck · 31 slides
Latest news
Relmada Therapeutics Appoints Uro-Oncology Leader Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officer
Nov 16, 2026
Closed $3.61 (-14.3%) on Nov 16, 2026
Relmada Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Nov 12, 2026
Closed $4.21 (+1.2%) on Nov 13, 2026
Relmada Therapeutics to Participate at the Jefferies Global Healthcare Conference in London
Nov 4, 2026
Closed $4.17 (-2.3%) on Nov 4, 2026
Relmada Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, November 12, 2026
Nov 3, 2026
Closed $4.27 (+11.2%) on Nov 3, 2026
Relmada Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference
Sep 1, 2026
Closed $4.46 (+2.3%) on Sep 1, 2026
Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Aug 6, 2026
Closed $4.94 (-8.0%) on Aug 7, 2026
Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer
Jul 28, 2026
Closed $5.23 (+0.6%) on Jul 28, 2026
Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
Jul 16, 2026
Closed $5.46 (-12.1%) on Jul 16, 2026
Relmada Therapeutics Joins Russell 2000® and Russell 3000® Indexes
Jun 29, 2026
Closed $6.98 (+4.3%) on Jun 29, 2026
Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program
Jun 11, 2026
Closed $6.52 (+2.2%) on Jun 11, 2026
Relmada Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 21 in the last 12 months · 111 in all · newest Nov 16, 2026 · oldest 2019
- Calls
- 24 calls with a replay · 24 with a transcript · latest Nov 12, 2026
- Decks
- 35 decks · latest Nov 12, 2026
Where Relmada Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:RLMD · Home listing | NASDAQ | United States | USD |
| gettex:4E2 | gettex | Germany | EUR |
| LS Exchange:A2PSZF | LS Exchange | Germany | EUR |
| Lang & Schwarz:A2PSZF | Lang & Schwarz | Germany | EUR |
| BOATS:RLMD | BOATS | United States | USD |
| Frankfurt:4E2 | Frankfurt | Germany | EUR |
| Tradegate:4E2 | Tradegate | Germany | EUR |
| Dusseldorf:4E2 · This page | Dusseldorf | Germany | EUR |
| Hamburg:4E2 | Hamburg | Germany | EUR |
| Munich:4E2 | Munich | Germany | EUR |
| Stuttgart:4E2 | Stuttgart | Germany | EUR |
Valuation
Price/book 1.4× against a median of 3.3×: 3rd lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $77.42M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 1.4×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.57
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Relmada Therapeutics, Inc. · NASDAQ:RLMD | US$279.5M | US$77.42M | n/a | n/a | n/a | 1.4× | n/a | 0.0× | 1.57 |
| Contineum Therapeutics, Inc. · NASDAQ:CTNM | US$286.1M | US$47.86M | n/a | n/a | n/a | 1.2× | n/a | 0.0× | 1.53 |
| TRex Bio, Inc. · NASDAQ:TRXB | US$283.1M | US$205.0M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Greenwich LifeSciences, Inc. · NASDAQ:GLSI | US$282.6M | US$276.7M | n/a | n/a | n/a | n/a | n/a | n/a | 2.80 |
| Precision BioSciences, Inc. · NASDAQ:DTIL | US$282.5M | US$228.3M | n/a | 5.1× | n/a | 5.5× | −85.6% | 0.5× | 0.30 |
| AP Biosciences, Inc. · TPEX:6945 | US$282.2M | US$215.6M | n/a | n/a | n/a | 4.0× | n/a | 0.0× | n/a |
| Fulcrum Therapeutics, Inc. · NASDAQ:FULC | US$281.8M | −US$17.87M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 0.42 |
| Circio Holding ASA · OSL:CRNA | US$281.1M | US$225.9M | n/a | n/a | n/a | 5.3× | n/a | 0.0× | n/a |
| Benitec Biopharma Inc. · NASDAQ:BNTC | US$276.1M | US$99.78M | n/a | n/a | n/a | 1.6× | n/a | 0.0× | 1.46 |
| Vicore Pharma Holding AB · OMXSTO:VICO | US$271.4M | US$182.7M | n/a | 467× | n/a | 3.3× | n/a | 0.0× | n/a |
| Galectin Therapeutics Inc. · NASDAQ:GALT | US$271.4M | US$293.0M | n/a | n/a | n/a | n/a | n/a | n/a | 1.20 |
| Median of the others | US$282.0M | US$210.3M | 236× | 3.3× | −85.6% | 0.0× | 1.33 |
Forecasts
3 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 10.75 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.41 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Sergio Traversa | Chief Executive Officer |
| Maged Shenouda | Chief Financial Officer |
| Paul Kelly | Chief Operating Officer |
| Bipin Dalmia | Chief Business Officer |
| Chuck Ence | Chief Accounting and Compliance Officer |
| Jørn Skibsted Jakobsen | Chief Development Officer, Urology & Uro-Oncology |
Board
| Director | Role |
|---|---|
| Charles J. Casamento | Chairman of the Board |
| Fabiana Fedeli | Director |
| John Glasspool | Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| Relmada Therapeutics (NASDAQ:RLMD) Q3 2026 Earnings Call | Thu, Nov 12, 2026 · 4:30 PM ET | Replay |
| Relmada Therapeutics (NASDAQ:RLMD) Q2 2026 Earnings Call | Thu, Aug 06, 2026 · 4:30 PM ET | Replay |
| Relmada Therapeutics (NASDAQ:RLMD) Q1 2026 Earnings Call | Tue, May 12, 2026 · 4:30 PM ET | Replay |
| Relmada Therapeutics (NASDAQ:RLMD) Q4 2025 Earnings Call | Thu, Mar 19, 2026 · 4:30 PM ET | Replay |
| Relmada Therapeutics (NASDAQ:RLMD) Q3 2025 Earnings Call | Thu, Nov 13, 2025 · 4:30 PM ET | Replay |
| Relmada Therapeutics (NASDAQ:RLMD) Q2 2025 Earnings Call | Thu, Aug 07, 2025 · 4:30 PM ET | Replay |
| Relmada Therapeutics (NASDAQ:RLMD) Q1 2025 Earnings Call | Mon, May 12, 2025 · 4:30 PM ET | Replay |
| Relmada Therapeutics (NASDAQ:RLMD) Q4 2024 Earnings Call | Thu, Mar 27, 2025 · 4:30 PM ET | Replay |
| Relmada Therapeutics (NASDAQ:RLMD) Q3 2024 Earnings Call | Thu, Nov 07, 2024 · 4:30 PM ET | Replay |
| Relmada Therapeutics (NASDAQ:RLMD) Q2 2024 Earnings Call | Wed, Aug 07, 2024 · 4:30 PM ET | Replay |
All 24 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 12, 2026 · After close | +1.2% |
| Q2 2026 | Aug 6, 2026 · After close | −8.0% |
| Q1 2026 | May 13, 2026 | −0.4% |
| Q4 2025 | Mar 19, 2026 · After close | −2.9% |
| Q3 2025 | Nov 13, 2025 · After close | +1.8% |
| Q2 2025 | Aug 7, 2025 | −1.9% |
| Q1 2025 | May 12, 2025 · After close | −2.1% |
| Q4 2024 | Mar 17, 2025 · After close | +0.4% |
| Q3 2024 | Nov 7, 2024 · After close | +0.6% |
| Q2 2024 | Aug 7, 2024 · After close | −29.0% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 8, 2024 · After close | −0.8% |
| Q4 2023 | Mar 19, 2024 · After close | −17.4% |
| Q3 2023 | Nov 8, 2023 · After close | −0.3% |
| Q2 2023 | Aug 8, 2023 · After close | +7.1% |
| Q1 2023 | May 11, 2023 · After close | −6.3% |
| Q4 2022 | Mar 23, 2023 · After close | −2.2% |
| Q3 2022 | Nov 10, 2022 · After close | +8.7% |
| Q2 2022 | Aug 11, 2022 · After close | +4.6% |
| Q1 2022 | May 5, 2022 · After close | −5.2% |
| Q4 2021 | Mar 23, 2022 · After close | +7.6% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 31 slides | Nov 12, 2026 |
| Investor Presentation (August 2026) | Investor deck | 32 slides | August 2026 |
| Investor Presentation (May 2026) | Investor deck | 40 slides | May 12, 2026 |
| Investor Presentation (March 2026) | Investor deck | 40 slides | Mar 20, 2026 |
| Technical Presentation (March 2026) | Technical | 12 slides | Mar 9, 2026 |
| Investor Presentation (November 2025) | Investor deck | 39 slides | Nov 13, 2025 |
| Investor Presentation (November 2025) | Investor deck | 39 slides | Nov 4, 2025 |
| Investor Presentation (September 2025) | Investor deck | 32 slides | Sep 17, 2025 |
| Investor Presentation (August 2025) | Investor deck | 36 slides | Aug 7, 2025 |
| Investor Presentation (October 2023) | Investor deck | 36 slides | Oct 4, 2023 |
All 35 decks
Financings
| Raise | Date |
|---|---|
| Public offering of common stock and pre-funded warrants Announced: about US$100M · US$2.2 a share · Jefferies +2 Dealers: Jefferies (co-lead), Leerink Partners (co-lead), Mizuho Buyers: Janus Henderson Investors; Ferring Ventures SA; Squadron Capital Management; Marshall Wace; Spruce Street Capital; OrbiMed; Columbia Threadneedle Investments; Driehaus Capital Management Use of proceeds: Working capital and general corporate purposes, including clinical studies and further development of product candidates | Nov 4, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2019 | FY2018 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
| Cost of revenue | 1.26K | 3.75K | 4.87K | 2.63K | ||||||
| Gross profit | -1.26K | -3.75K | -4.87K | -2.63K | ||||||
| Research and development | 26.9M | 46.2M | 54.8M | 113.3M | 90.6M | 36.0M | 7.86M | 7.02M | 2.94M | 2.94M |
| Selling, general and administrative | 311.9K | 37.7M | 48.9M | 47.9M | 35.1M | 24.9M | 7.25M | 3.98M | ||
| Operating income | -59.1M | -83.9M | -103.7M | -161.2M | -125.7M | -60.8M | -15.1M | -12.7M | -6.92M | -6.92M |
| Depreciation and amortization | 83.9M | 103.7M | 2.00K | 1.26K | 3.75K | 4.36K | 4.87K | 2.63K | 2.63K | |
| EBITDA | -36 | -293 | -161.2M | -125.7M | -60.8M | -15.1M | -12.7M | -6.91M | -6.91M | |
| Interest expense | 4.21M | 48.3K | 1.40M | 1.34M | ||||||
| Income before tax | -57.4M | -80.0M | -98.8M | -157.0M | -125.8M | -59.5M | -15.0M | -8.96M | ||
| Income tax | -103.7K | -2.66M | 48.3K | -1.38M | 4.59M | 2.05M | ||||
| Net income | -57.4M | -80.0M | -98.8M | -157.0M | -125.8M | -59.5M | -15.0M | -17.3M | -8.96M | -8.96M |
| Earnings per share, basic | -1.45 | -2.65 | -3.28 | -5.30 | -7.16 | -3.81 | -1.62 | -2.74 | -2.86 | -2.86 |
| Earnings per share, diluted | -1.45 | -2.65 | -3.28 | -5.30 | -7.16 | -3.81 | -1.62 | -2.74 | -2.86 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2019 | FY2018 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 3.50M | 3.86M | 4.09M | 5.40M | 44.4M | 2.50M | 36.3M | 9.22M | 2.24M | 2.24M |
| Short-term investments | 89.5M | 41.1M | 92.2M | 142.9M | 167.5M | 114.6M | 80.2M | |||
| Receivables | 512.4K | 86.4K | 79.5K | 73.1K | 72.1K | |||||
| Inventory | 4.04M | 11.3M | 903.2K | 459.0K | 426.9K | |||||
| Current assets | 94.0M | 45.8M | 97.5M | 152.9M | 223.3M | 118.1M | 116.9M | 9.98M | 2.74M | 2.74M |
| Property, plant and equipment | 1.26K | 5.01K | 7.21K | 7.21K | 12.1K | |||||
| Total assets | 94.0M | 45.8M | 97.6M | 152.9M | 223.3M | 118.2M | 117.1M | 10.2M | 3.05M | 3.05M |
| Accounts payable | 1.57M | 4.13M | 3.51M | 5.26M | 11.2M | 8.35M | 522.7K | 924.4K | 765.4K | 765.4K |
| Current liabilities | 6.43M | 10.3M | 12.2M | 12.5M | 15.1M | 12.6M | 1.46M | 2.61M | 5.90M | 5.90M |
| Total debt | 110.2K | 2.94M | ||||||||
| Total liabilities | 7.49M | 10.3M | 12.2M | 12.5M | 15.1M | 12.6M | 1.46M | 2.61M | 8.56M | 8.56M |
| Shareholders' equity | 86.5M | 35.5M | 85.4M | 140.4M | 208.3M | 105.6M | 115.7M | 7.61M | -5.51M | -5.51M |
| Shares outstanding | 73.3M | 30.2M | 30.1M | 30.1M | 27.7M | 16.3M | 14.5M | 9.74M | 3.14M | 3.14M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2019 | FY2018 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -45.8M | -51.8M | -51.7M | -103.8M | -91.9M | -27.8M | -12.1M | -10.5M | -6.00M | -6.00M |
| Capital spending | 0 | 0 | -4 | -3 | -5 | -182.1M | -84.8M | -12.4K | -12.4K | |
| Free cash flow | -45.8M | -51.8M | -51.7M | -103.8M | -91.9M | -209.9M | -96.9M | -6.01M | -6.01M | |
| Cash from investing | -48.1M | 51.6M | 50.5M | 19.7M | -54.1M | -34.4M | -80.2M | -12.4K | -12.4K | |
| Cash from financing | 93.6M | -40.3K | -98.5K | 45.0M | 187.9M | 28.5M | 126.1M | 17.5M | 6.54M | 6.54M |
| Share buybacks | 42.7M | 113.9M | 17.8M | |||||||
| Change in cash | -360.5K | -234.5K | -1.30M | -39.0M | 41.9M | -33.8M | 33.9M | 6.98M | 528.4K | 528.4K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Nov 16, 2026 | Current report | SEC |
| 8-K · Current report | Nov 12, 2026 | Results | SEC |
| 10-Q · Quarterly report | Nov 12, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Sep 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 11, 2026 | Insider trade | SEC |
| 8-K · Current report | Sep 8, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Aug 6, 2026 | Results | SEC |
| 10-Q · Quarterly report | Aug 6, 2026 | Quarterly report | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G · Big-stake notice | Jul 29, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jul 28, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Jun 22, 2026 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Jun 18, 2026 | Offer document | SEC |
| SCHEDULE 13G · Big-stake notice | Jun 9, 2026 | Big-stake notice | SEC |
| 8-K · Current report | May 28, 2026 | Meeting outcome | SEC |
| S-3ASR · Registration statement | May 13, 2026 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 13, 2026 | Big-stake notice | SEC |
| 8-K · Current report | May 12, 2026 | Results | SEC |
| 10-Q · Quarterly report | May 12, 2026 | Quarterly report | SEC |
| SCHEDULE 13G · Big-stake notice | May 4, 2026 | Big-stake notice | SEC |
| DEFA14A · Additional proxy material | Apr 17, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 17, 2026 | Meeting notice | SEC |
| EFFECT · Notice that a registration is effective | Apr 10, 2026 | Other filings | SEC |
| 424B3 · Prospectus | Apr 9, 2026 | Offer document | SEC |
| CORRESP · Letter to the SEC | Apr 7, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Apr 7, 2026 | Other filings | SEC |
| PRE 14A · Preliminary proxy statement | Apr 6, 2026 | Meeting notice | SEC |
| S-3 · Registration statement | Apr 3, 2026 | Offer document | SEC |
| 8-K · Current report | Mar 20, 2026 | Results | SEC |
| 10-K · Annual report | Mar 19, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 9, 2026 | Material contract | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 12, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 6, 2026 | Big-stake notice | SEC |
| 424B5 · Prospectus | Jan 30, 2026 | Offer document | SEC |
| 4 · Change in ownership | Dec 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 16, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 15, 2025 | Management or board change | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Nov 13, 2025 | Results | SEC |
| 10-Q · Quarterly report | Nov 13, 2025 | Quarterly report | SEC |
| 4 · Change in ownership | Nov 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 6, 2025 | Insider trade | SEC |
| 8-K · Current report | Nov 4, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Nov 4, 2025 | Offer document | SEC |
| FWP · Free writing prospectus | Nov 4, 2025 | Offer document | SEC |
| 8-K · Current report | Nov 4, 2025 | Current report | SEC |
| 8-K · Current report | Sep 17, 2025 | Current report | SEC |
| 8-K · Current report | Sep 16, 2025 | Current report | SEC |
| 8-K · Current report | Sep 10, 2025 | Current report | SEC |
| 8-K · Current report | Sep 2, 2025 | Current report | SEC |
| 4 · Change in ownership | Aug 28, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Aug 7, 2025 | Results | SEC |
| 10-Q · Quarterly report | Aug 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | Jul 23, 2025 | Current report | SEC |
| 8-K · Current report | Jul 10, 2025 | Current report | SEC |
| 4 · Change in ownership | Jun 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 30, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 17, 2025 | Current report | SEC |
| S-8 · Registration statement for employee plans | Jun 12, 2025 | Offer document | SEC |
| 8-K · Current report | May 27, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | May 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | May 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 12, 2025 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | May 1, 2025 | Big-stake notice | SEC |
| 424B5 · Prospectus | Apr 28, 2025 | Offer document | SEC |
| 8-K · Current report | Apr 28, 2025 | Current report | SEC |
| DEFA14A · Additional proxy material | Apr 11, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 11, 2025 | Meeting notice | SEC |
| 8-K · Current report | Mar 27, 2025 | Results | SEC |
| 10-K · Annual report | Mar 27, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 26, 2025 | Material contract | SEC |
| 8-K · Current report | Feb 6, 2025 | Material contract | SEC |
| 8-K · Current report | Jan 27, 2025 | Current report | SEC |
| 8-K · Current report | Jan 6, 2025 | Management or board change | SEC |
| 8-K · Current report | Dec 9, 2024 | Current report | SEC |
| 8-K · Current report | Dec 4, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 7, 2024 | Quarterly report | SEC |
| 4 · Change in ownership | Oct 23, 2024 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Sep 13, 2024 | Other filings | SEC |
| 4 · Change in ownership | Sep 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 11, 2024 | Insider trade | SEC |
| CORRESP · Letter to the SEC | Sep 11, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Sep 6, 2024 | Other filings | SEC |
| S-3 · Registration statement | Aug 30, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 30, 2024 | Meeting outcome | SEC |
| 4 · Change in ownership | May 29, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | May 8, 2024 | Quarterly report | SEC |
| DEFA14A · Additional proxy material | Apr 9, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 9, 2024 | Meeting notice | SEC |
| 8-K · Current report | Mar 19, 2024 | Results | SEC |
| 10-K · Annual report | Mar 19, 2024 | Annual report | SEC |
| SC 13G/A · Big-stake notice, amended | Mar 6, 2024 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Feb 20, 2024 | Other filings | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 13, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 31, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 31, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 31, 2024 | Insider trade | SEC |
| 8-K · Current report | Jan 11, 2024 | Management or board change | SEC |
| 8-K · Current report | Jan 4, 2024 | Current report | SEC |
| 8-K · Current report | Jan 3, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Dec 19, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 19, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 19, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 19, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 19, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 19, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 19, 2023 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 8, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 8, 2023 | Results | SEC |
| 8-K · Current report | Oct 11, 2023 | Current report | SEC |
| 8-K · Current report | Oct 10, 2023 | Current report | SEC |
| 8-K · Current report | Oct 4, 2023 | Current report | SEC |
| 8-K · Current report | Sep 20, 2023 | Current report | SEC |
| 8-K · Current report | Sep 6, 2023 | Management or board change | SEC |
| 8-K · Current report | Aug 10, 2023 | Current report | SEC |
| 8-K · Current report | Aug 8, 2023 | Results | SEC |
| 10-Q · Quarterly report | Aug 8, 2023 | Quarterly report | SEC |
| SC 13G/A · Big-stake notice, amended | Jul 7, 2023 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Jun 21, 2023 | Offer document | SEC |
| 4 · Change in ownership | May 30, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 30, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 30, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 30, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 30, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 30, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 30, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 30, 2023 | Insider trade | SEC |
| 8-K · Current report | May 25, 2023 | Management or board change | SEC |
| 4 · Change in ownership | May 24, 2023 | Insider trade | SEC |
| 8-K · Current report | May 15, 2023 | Current report | SEC |
| 8-K · Current report | May 11, 2023 | Results | SEC |
| 10-Q · Quarterly report | May 11, 2023 | Quarterly report | SEC |
| 8-K · Current report | Apr 19, 2023 | Current report | SEC |
| DEFA14A · Additional proxy material | Mar 31, 2023 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Mar 31, 2023 | Meeting notice | SEC |
| 10-K · Annual report | Mar 23, 2023 | Annual report | SEC |
| 8-K · Current report | Mar 23, 2023 | Results | SEC |
| 8-K · Current report | Mar 13, 2023 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2023 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2023 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2023 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2023 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2023 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2023 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 9, 2023 | Big-stake notice | SEC |
| 5/A · Annual statement of ownership, amended | Feb 6, 2023 | Insider trade | SEC |
| 5 · Annual statement of ownership | Feb 2, 2023 | Insider trade | SEC |
| 5 · Annual statement of ownership | Feb 2, 2023 | Insider trade | SEC |
| 5 · Annual statement of ownership | Feb 2, 2023 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 1, 2023 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Jan 13, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 13, 2023 | Insider trade | SEC |
| 8-K · Current report | Jan 13, 2023 | Material contract | SEC |
| 8-K · Current report | Jan 9, 2023 | Current report | SEC |
| 8-K · Current report | Jan 5, 2023 | Material contract | SEC |
| 8-K · Current report | Dec 28, 2022 | Material contract | SEC |
| 4 · Change in ownership | Dec 20, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Dec 20, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Dec 20, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Dec 20, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Dec 20, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Dec 20, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Dec 20, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Dec 20, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Dec 20, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Dec 20, 2022 | Insider trade | SEC |
| SC 13G · Big-stake notice | Dec 20, 2022 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 12, 2022 | Insider trade | SEC |
This page holds 200 of 610 filings. Open Filings
Cap table
Built by 6ix from Relmada Therapeutics, Inc.’s releases · as of Nov 10, 2026
- Common shares
- 106,694,846
- Fully diluted
- 106,694,846
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 106,694,846 | Nov 10, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 10, 2026 | 106,694,846 |
| Nov 10, 2026 | 106,694,846 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Charles J. Casamento Other companies: GT Biopharma, Inc. (Director · Since at least May 1, 2023); Eton Pharmaceuticals, Inc. (Director · Since at least Nov 9, 2018); PaxMedica, Inc. (Director · Oct 1, 2022 – Mar 12, 2024 · Past); GridAI Technologies Corp. (Director · Mar 3, 2017 – Jan 2, 2024 · Past); International Stem Cell Corporation (Director · Mar 31, 2016 – Jun 21, 2018 · Past) | Chairman of the Board · Since at least Oct 20, 2017 |
| Douglas Beck Other companies: SHF Holdings, Inc. (PAO SVP of Finance Controller · Since at least Sep 24, 2025); ShiftPixy Inc (Chief Financial Officer · Jan 15, 2023 – Jan 15, 2023 · Past); Beyond Air, Inc. (Chief Financial Officer · Nov 1, 2018 – Jun 16, 2021 · Past); iBio, Inc. (Chief Financial Officer · May 3, 2011 – May 3, 2011 · Past); Lev Pharmaceuticals Inc (Chief Financial Officer · Jun 7, 2006 – Jun 7, 2006 · Past) | Chief Financial Officer · Jan 6, 2015 – Feb 23, 2015 · Past |
| Eric Thomas Schmidt Other companies: Revolution Medicines, Inc. (Director · Jun 17, 2020 – Jun 8, 2023 · Past); Allogene Therapeutics, Inc. (Chief Financial Officer · Oct 10, 2018 – Mar 22, 2023 · Past) | Director · Dec 19, 2019 – May 25, 2023 · Past |
| Maged Shenouda Other companies: GridAI Technologies Corp. (CHIEF FINANCIAL OFFICER, Director · Oct 11, 2016 – Dec 28, 2018 · Past); Protea Biosciences Group (Director · Apr 17, 2015 – Dec 18, 2015 · Past) | Chief Financial Officer · Since at least Nov 12, 2015 |
| Chuck Ence Other companies: Newage Inc (Chief Financial Officer · Sep 15, 2016 – Sep 15, 2016 · Past) | Chief Accounting and Compliance Officer · Since at least Jul 29, 2019 |
| Lisa Nolan Other companies: Opus Genetics, Inc. (Chief Business Officer · Jul 6, 2016 – Feb 28, 2019 · Past) | Chief Business Officer · Dec 14, 2015 – Dec 14, 2015 · Past |
| Sandesh Seth Other companies: Actinium Pharmaceuticals, Inc. (Delaware) (Chief Executive Officer and Chairman of the Board · Since at least Dec 28, 2012) | Director · Jan 6, 2015 – Dec 15, 2015 · Past |
| Sergio Traversa Other companies: Actinium Pharmaceuticals, Inc. (Delaware) (Director · Dec 28, 2012 – Mar 14, 2017 · Past) | Chief Executive Officer · Since at least Jan 6, 2015 |
| Thomas Wessel Other companies: Decoy Therapeutics Inc. (Chief Medical Officer · Jan 17, 2018 – Jan 17, 2018 · Past) | EVP, Head of R&D · Mar 9, 2020 – Mar 9, 2020 · Past |
| Bipin Dalmia | Chief Business Officer · Since Jul 28, 2026 |
All 19 people
| Person | Seat |
|---|---|
| Cedric O'Gorman | Chief Medical Officer · Jan 6, 2023 – May 23, 2023 · Past |
| Fabiana Fedeli | Director · Since at least Jan 12, 2023 |
| John Glasspool | Director · Since at least Dec 17, 2021 |
| Jørn Skibsted Jakobsen | Chief Development Officer, Urology & Uro-Oncology · Since Nov 16, 2026 |
| Nabil Yazgi | Director · Jan 6, 2015 – Jan 6, 2015 · Past |
| Ottavio V Vitolo | CMO · Apr 2, 2018 – Dec 19, 2019 · Past |
| Paul Kelly | Chief Operating Officer · Since at least Nov 12, 2015 |
| Shreeram Agharkar | Director · Dec 16, 2015 – Dec 31, 2015 · Past |
| Yair Lotan | Chair of Relmada’s Clinical Advisory Board · Jul 15, 2025 – Nov 4, 2026 · Past |
Log in to ask 6ix AI your own questions about Relmada Therapeutics, Inc.